Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.
The following faculty indicated no significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:
Oscar Fernàndez
Angelo Ghezzi
Carlos Nos Llopis
Jordi Rio
Álex Rovira
Mireia Sospedra
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:
Giancarlo Comi: Declared receipt of honoraria or consultation fees from Serono Symposia International Foundation, Bayer-Schering, Teva Pharmaceutical Industries, Merck Serono, Novartis, Dompè Biogen and Sanofi-Aventis.
Roland Martin: Declared receipt of grants and contracts from Biogen, receipt of honoraria or consultation fees from Merck Serono and Roche. He declared to be member of Merck Serono advisory board and participation in Sanofi Aventis and Merck Serono speaker’s bureau. His presentation might include off-label use of “daclizumab”, which will be clearly declared by the speaker during the presentation.
Xavier Montalban: Declared receipt of honoraria or consultation fees from Bayer-Schering, Biogen Idec, Teva and Sanofi-Aventis.
Magnhild Sandberg-Wollheim: Declared receipt of grants and contracts from Merck Serono, Serono Nordic and Genentech and honoraria or consultation fees from Sanofi-Aventis, Bayer Health Care, SSIF and Active Biotech. She declared also to be member of Active Biotech board of directors.
Jaume Sastre-Garriga: Declared participation in a Bayer-Schering, Merck Serono and Sanofi-Aventis sponsored speaker’s bureau.
Mar Tintoré: Declared receipt of grants and contracts and honoraria or consultation fees from Bayer Schering, Biogen-Idec, Merck Serono and Teva Sanofi.
Maria Trojano: Declared receipt of research support from Biogen Idec, Merck Serono, Sanofi-Aventis Pharmaceuticals and Bayer-Schering. She received also fees for speaking from Biogen Idec, Merck Serono, Sanofi-Aventis Pharmaceuticals and Bayer-Schering.
